Swiss precision oncology biotech FoRx Therapeutics has secured a EUR 50 million Series A led by repeat backers EQT Life Sciences, Novartis Venture Fund and Pfizer Ventures, with M Ventures participating. Proceeds fund Phase I development of lead asset FORX-428 with data expected by mid-2026.